© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Jun 24, 2016, the consensus forecast amongst 3 polled investment analysts covering CTI BioPharma Corp advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 10, 2016. The previous consensus forecast advised that CTI BioPharma Corp would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 3 analysts offering 12 month price targets for CTI BioPharma Corp have a median target of 0.75, with a high estimate of 5.00 and a low estimate of 0.00. The median estimate represents a 108.80% increase from the last price of 0.3592. View Full Financials
Dividend information is not available for CTi Biopharma Corp. View Full Financials
On May 10, 2016, CTI BioPharma Corp reported 1st quarter 2016 earnings of 0.01 per share. This result exceeded the -0.04 consensus loss of the one analyst covering the company and outperformed last year's 1st quarter results by 0.17.
The next earnings announcement is expected on Aug 04, 2016. View Full Interim Financials
|Average growth rate||+4.76 %|
CTI BioPharma Corp reported annual 2015 losses of -0.65 per share on Feb 16, 2016. View Full Annual Financials
|Average growth rate||+19.02 %|
CTI BioPharma Corp. had 1st quarter 2016 revenues of 36.48m. This bettered the 20.91m estimate of the one analyst covering the company. This was 1,237.06% above the prior year's 1st quarter results. View Full Interim Financials
|Average growth rate||+306.19 %|
CTI BioPharma Corp. had revenues for the full year 2015 of 16.12m. This was 73.17 % below the prior year's results. View Full Annual Financials
|Average growth rate||+807.69 %|